Topic

global manufacturing

1 article

Strides Pharma delivers strong FY26 performance with 50% PAT growth, ex‑US markets up 21%
News 19 May 2026

Strides Pharma delivers strong FY26 performance with 50% PAT growth, ex‑US markets up 21%

Strides Pharma Science Ltd. reported a robust FY26 performance, with consolidated EBITDA rising to ₹9,253 crore and operational profit after…